Zoetis Inc logo

ZTS - Zoetis Inc Share Price

$128.75 1.5  1.2%

Last Trade - 09/04/20

Large Cap
Market Cap £48.80bn
Enterprise Value £52.44bn
Revenue £5.05bn
Position in Universe 139th / 6317
Unlock ZTS Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZTS Revenue Unlock ZTS Revenue

Net Income

ZTS Net Income Unlock ZTS Revenue

Normalised EPS

ZTS Normalised EPS Unlock ZTS Revenue

PE Ratio Range

ZTS PE Ratio Range Unlock ZTS Revenue

Dividend Yield Range

ZTS Dividend Yield Range Unlock ZTS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZTS EPS Forecasts Unlock ZTS Revenue
Profile Summary

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated July 25, 2012
Public Since February 1, 2013
No. of Shareholders: 1,795
No. of Employees: 10,600
Sector Healthcare
Industry Pharmaceuticals
Index S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Shares in Issue 474,933,945
Free Float (0.0%)
Eligible for
ZTS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZTS
Upcoming Events for ZTS
Thursday 16th April, 2020
Dividend For Z1TS34.SA - 0.2168 BRL
Thursday 16th April, 2020
Dividend For ZTS.N - 0.2000 USD
Thursday 30th April, 2020 Estimate
Q1 2020 Zoetis Inc Earnings Release
Wednesday 6th May, 2020
Q1 2020 Zoetis Inc Earnings Call
Thursday 14th May, 2020 Estimate
Zoetis Inc Annual Shareholders Meeting
Wednesday 20th May, 2020
Zoetis Inc Annual Shareholders Meeting
Tuesday 4th August, 2020 Estimate
Q2 2020 Zoetis Inc Earnings Release
Similar to ZTS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.